Skloot, Gwen S.
Guasconi, Alessandro
Lavon, Benjamin R.
Georges, George
De Backer, Wilfried
Galkin, Dmitry
Cortellini, Mauro
Panni, Ilaria
Bates, Jason H. T.
Clinical trials referenced in this document:
Documents that mention this clinical trial
The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
https://doi.org/10.1186/s12931-023-02549-5
Article History
Received: 6 September 2023
Accepted: 29 September 2023
First Online: 6 October 2023
Declarations
:
: All patients provided written informed consent prior to any study-related procedure. The study was approved by independent ethics committees at each institution, and was performed in accordance with the principles of the Declaration of Helsinki, and the International Conference on Harmonisation notes for guidance on Good Clinical Practice (ICH/CPMP/135/95).
: Not applicable.
: GSS, AG, GG, DG, MC and IP are employees of Chiesi. In addition, DG owns shares in GlaxoSmithKline. BRL is an employee of Fluidda, the company that owns and implements FRI, and that was engaged by Chiesi to conduct the quantitative CT analysis referred to in the manuscript. WDB is a board member of Fluidda. JHTB declares consulting fees from Chiesi within the scope of this manuscript. Outside the scope of the manuscript he declares an NHLBI grant paid to his institution, and stock or stock options from Oscillavent, LLC.